Cambridge, Mass.-based Genzyme Corp. submitted marketing applications in the U.S and Europe for its lymphoma and multiple myeloma treatment Mozobil (plerixafor), a small-molecule CXCR4 chemokine receptor antagonist. (BioWorld Today)

Shares of Acadia Pharmaceuticals Inc. plunged 43 percent Monday on news that its experimental schizophrenia drug, ACP-104, failed to meet its primary endpoint of antipsychotic efficacy in a 247-patient Phase IIb study. (BioWorld Today)

WASHINGTON - As the FDA sets out to implement its congressional mandate to develop a national active surveillance network for monitoring medical products, the agency must first and foremost ensure that the privacy of patients is not breached, health policy experts said. (BioWorld Today)

Research and discovery tools firm Invitrogen Corp. has agreed to buy Applied Biosystems Group, a subsidiary of Applera Corp. that develops and markets systems for analyzing nucleic acids, proteins and small molecules, for $6.7 billion in cash and stocks.(BioWorld Today)

Centocor Inc. and its partner Schering-Plough Corp. said their investigational rheumatoid arthritis drug golimumab (CNTO 148), a next-generation human antitumor necrosis factor (TNF)-alpha monoclonal antibody, met its primary endpoint in three separate Phase III studies. (BioWorld Today)